DBV Technologies

DBV Technologies is a global clinical stage biopharmaceutical company founded in 2002 by pediatricians with a vision to develop safe and effective treatments for food allergies. The company is dedicated to advancing epicutaneous immunotherapy using its innovative technology platform, Viaskin™. DBV Technologies is committed to addressing the unmet medical needs in immunologic diseases. The company's focus lies in pioneering a potential new class of immunotherapy called epicutaneous immunotherapy (EPIT), which aims to re-educate the patient's immune system through the skin. Currently, the company is primarily exploring Viaskin for addressing food allergies, particularly peanut allergy, affecting millions of patients. Their recent €181.00M Post-IPO Equity investment on 09 June 2022 was led by notable investors including Bpifrance, RA Capital Management, Vivo Capital, Fairmount Funds, Braidwell, Venrock Healthcare Capital Partners, and Baker Brothers Advisors LLC. In the future, the company aims to explore broader applications of this immunotherapy, potentially including treatments for inflammatory and autoimmune diseases.